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An online programme to reduce depression 
in patients with multiple sclerosis: a 
randomised controlled trial  Anja Fischer*, Johanna 
Schröder*, Eik Vettorazzi, Oliver T Wolf, Jana Pöttgen, Stephanie Lau, Christoph Heesen, Ste en 
Moritz†, Stefan M Gold†  
Summary  Background With a lifetime risk for major depressive disorder of up to 
50%, depression is a common comorbidity in multiple sclerosis but remains widely 
underdiagnosed and untreated. We investigated the potential of a fully automated, 
internet-based, cognitive behavioural therapy programme, Deprexis, to reduce depressive 
symptoms in patients with multiple sclerosis.  
Methods For this randomised controlled trial, we recruited patients from an outpatient 
clinic in Hamburg, Germany. Patients aged 18–65 years were eligible for inclusion if they 
had multiple sclerosis and self-reported depressive symptoms. By use of a computer-
generated randomisation sequence, we allocated 90 patients (1:1; no blocking or strati 
cation) to either the intervention group or a waitlist control group for 9 weeks. The 
primary endpoint was the Beck Depression Inventory (BDI), as assessed by an intention-to-
treat analysis. This trial is registered with ClinicalTrials.gov, number NCT01663649.  
Findings 71 patients completed the trial: 35 patients in the intervention group and 36 
patients in the control group. During the intervention, BDI scores decreased in the 
Deprexis group and increased in the control group, yielding a positive e ect of Deprexis 
relative to the waitlist group (mean group di erence –4·02 points [95% CI –7·26 to –0·79], 
p=0·015, e ect size d=0·53). Worsening of depressive symptoms from below to above the 
clinical cuto (BDI >13) occurred in three (7%) of 45 patients in the control group and no 
patients in the Deprexis group. We noted no adverse events with respect to new occurrence 
of suicidal ideation during the trial.  
Interpretation Psychological online-intervention programmes could be suitable for patients 
with multiple sclerosis who are unable to regularly attend therapeutic sessions because of 
mobility impairments.  
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Multiple sclerosis is an in ammatory, demyelinating neurodegenerative disease of the CNS. In 
addition to motor dysfunction, visual and other sensory impairment, patients with the disorder 
often have neuropsychiatric symptoms such as depressed mood, fatigue, and cognitive 
impairment. Depression is especially common in this group of patients who have a lifetime risk 
for major de- pressive disorder as high as 25–50%,1 and a 12 months’ prevalence of up to 25%.2 
Depression in multiple sclerosis has been linked to biological as well as psychological factors 
and substantially a ects psychosocial function.3 Depressive symptoms correlate with decreased 
quality of life, absence from work, and lower social support in patients with multiple sclerosis.4,5 
Depression is also associated with lower immunotherapy adherence rates and might thus have 
direct consequences for overall health outcome.6 Moreover, depression is one of the main 
predict- ors for suicidal ideation and suicide risk in patients with muliple sclerosis.7 If left 
untreated, depressive symptoms in multiple sclerosis rarely remit spontaneously, often become 
chronic,8 and can worsen over time, particularly in patients with scores indicative of clinical 
depression at the study baseline.9 Despite its immediate clinical relevance, depression remains 
widely underdiagnosed and untreated in patients with multiple sclerosis.10  
We are aware of only two previous placebo-controlled, randomised trials to have assessed the e 
ects of pharmacotherapy with desipramine and paroxetine in depression in patients with multiple 
sclerosis.11,12 Findings from a Cochrane review13 showed that some bene ts were apparent—albeit 
not statistically signi cant for most endpoints—but that adverse side- e ects such as nausea and 
headaches were a concern. Findings from a systematic review and meta-analysis suggested that 
cognitive behavioural therapy (CBT) might be bene cial in reducing depressive symptoms in 
patients with multiple sclerosis.14 However, the American Academy of Neurology’s 2014 
guidelines for psychiatric disorders in patients with multiple sclerosis have pointed out that more 
research is needed.15 In particular, a need exists to develop and rigidly test the e cacy of treatment 
strategies for multiple-sclerosis- associated depression and to facilitate access to these 
treatments. Because multiple sclerosis often causes motor impairment and decreased mobility as 
well as increased fatigue and cognitive problems, remote access options for psychotherapy might 
be useful to enhance availability of e ective depression inter- ventions such as CBT for these 
patients. For example, psychotherapy delivered by phone has been shown to decrease depressive 
symptoms in patients with multiple sclerosis.16,17 Such approaches, however, still require 
availability of a trained psychotherapist.  
We tested the feasibility and e cacy of a fully automated, internet-based CBT (iCBT) programme 
(Deprexis),18 which has been shown to be e ective in patients with depression without comorbid 
somatic disorders,19 to reduce depressive symptoms in patients with multiple sclerosis.  
Methods  
Study design and population  
In this randomised controlled trial, we contacted by mail patients registered in the database of the 
multiple sclerosis outpatient clinic at the University Medical Centre Hamburg-Eppendorf, 
Germany, whose scores from their last clinical visit indicated depressive symptoms (as measured 
by the mood subscale of the Hamburg Quality of Life Questionnaire for Multiple Sclerosis 
(HAQUAMS).20 Additionally, we recruited participants via online forums following guidelines of 
the Hamburg Department of Data Security. Participation was free of charge.  
Patients were eligible for inclusion if they were aged 18–65 years, had a diagnosis of multiple 
sclerosis, self- reported depressive symptoms, and willingness to self- administrate iCBT 
sessions for 9 weeks. Participants were excluded if they did not consent to participation, were 
diagnosed with bipolar or schizophrenia spectrum disorders, had substantial neurocognitive 
impairment such as dementia, or had suicidal ideations. We used a secure online-survey 
programme EFS survey) to screen for inclusion and exclusion criteria before randomisation. A 
subgroup of the total sample volunteered to complete in-person visits to our multiple sclerosis 
outpatient centre before and after the intervention. The aim of this subgroup analysis was to 
validate depressive sympto- matology by means of additional questionnaires and structured 
interviews.  
Written informed consent was provided via the online platform. The study was approved by the 
ethics committee of the German Society of Psychology.  
Randomisation and masking  
We allocated eligible patients to either intervention group or a waitlist control group (WLC; 1:1) 
using a computer- generated randomisation sequence with no strati cation or blocking. JS was in 
charge of generating the random sequence. None of the other investigators had access to the 
random sequence at any time. Patients were allocated 
strictlyaccordingtotheorder(dateandexacttimeofday) 
inwhichtheyhadcompletedtheonlinecheckofeligibility and baseline assessments of questionnaires 
as logged by the unipark system, ensuring that the eligibility check was blind to treatment 
allocation (concealed allocation). JS later was responsible for sending standardised email 
reminders to complete the online survey to every participant at pre-de ned times for follow-up 
assessment and contributed to writing the report.  
Masking of the participants regarding treatment allocation was not possible due to the nature of 
the information (ie, behavioural intervention). All outcome measures were collected via an 
automated online interface, so that masking of the assessors was not necessary. For the subgroup 
in which outcome measures were collected in person, we made substantial e ort to ensure that all 
patients were assessed by a clinician masked to group assignment—ie, the appointments were 
scheduled and patients were debriefed by sta members not involved in their assessment, and 
participants were instructed not to reveal their group assignment to the examiners at the clinic.  
Procedures  
Deprexis is an online programme based on principles of CBT. It consists of ten sequential 
modules—psycho- education, behavioural activation, cognitive modi cation, mindfulness and 
acceptance, interpersonal skills, relaxation, physical exercise and lifestyle modi cation, problem 
solving, expressive writing and forgiveness, positive psychology, and emotion-focus 
interventions— plus an introduction and a summary module. It implements the technique of 
simulated dialogue by giving the user multiple-choice options and tailors the subsequent options 
to the patient’s responses. The user’s responses thus determine the course of each module. 
Dependent on the user’s speed, each module can be completed in less than 60 mins. The 
programme is described in detail elsewhere.18 Participants randomly assigned to the control group 
were o ered full access to Deprexis on completion of the study.  
Outcomes  
All outcome measures—a set of questionnaires administered online to measure depressive 
symptoms, quality of life, and fatigue—were obtained at baseline  
Figure 1: Trial chart  
and 9 weeks after enrolment (ie, before and after the 9 week long programme for the Deprexis 
group and before and after waiting for 9 weeks for the waitlist group). We did a follow-up 
assessment 6 months after the end of the intervention using the same online platform.  
Self-report questionnaires obtained online are similar to written questionnaires in terms of 
reliability and validity,21 as shown for depression scales including the Beck Depression Inventory 
(BDI).22  
The primary endpoint of the study was severity of depressive symptoms as measured by the 
BDI.23 We analysed the BDI total score (primary endpoint) as well as BDI subscale scores 
(post-hoc analysis). The secondary endpoints were quality of life, as measured by the WHO 
Quality of Life scale (WHO-QoL BREF),24 disease-related quality of life (measured by 
HAQUAMS),20 and fatigue (Fatigue Scale For Motor And Cognitive Function; FSMC).25 We also 
screened for suicidal ideation and behaviour (with Suicide Behaviors Questionnaire- Revised 
[SBQ-R]), as a prede ned safety measure.26  
In the clinical subgroup, patients underwent a structured clinical interview (The Mini 
International Neuropsychiatric Interview; MINI)27 administered by a trained clinician. They also 
completed an additional depression questionnaire (Inventory of Depressive Symptomatology; 
IDS-30SR).28 In this subgroup, we analysed the IDS total score as well as published IDS 
cognitive and somatic subscales.29  
To assess treatment adherence we used data from the Deprexis interface, which tracks usage time 
of each participant. The usage log of Deprexis uses 5-min blocks and excludes each block of 
inactivity so that the logged usage times is a good estimate of time spent working with the 
programme. To assess the acceptance of Deprexis by patients, we obtained retrospective 
appraisal of the programme from participants randomised to the Deprexis group (appendix A).  
We did not include a data monitoring committee to assess adverse events. However, we collected 
self- reported data for suicidal ideation and behaviour using the SBQ-R as a prede ned safety 
measure. If responses indicated acute risk of suicide (response 3a or 3b on SBQ-R item 3 plus 
score of 5 or 6 on SBQ-R item 4), patients were provided automatically with emergency contact 
numbers on the computer screen. To test for incidental evidence of adverse events, we also used 
a lower threshold for suicidal ideation (score >1 on item 9 of the BDI or score >3 on item 4 of 
the SBQ-R). We also regarded worsening of depressive symptoms during the trial from below to 
above the cuto for so-called caseness for clinical depression (BDI >13) as an adverse event.  
Statistical analysis  
Power calculation for the trial was based on results obtained from a previously published study 
using Deprexis in a cohort of patients with psychiatric disorders without comorbid somatic 
disorders.18 The pre–post  
See Online for appendix A  
-insert tabke here- 
Data are n (%) or mean (SD). HAQUAMS=Hamburg Quality of Life Questionnaire in Multiple Sclerosis. NaSSA=noradrenergic 
and speci c serotonergic antidepressant. SNRI=selective serotonin and noradrenaline reuptake inhibitors. SSRI=selective 
serotonin reuptake inhibitor. TCA=tricyclic antidepressants.  
Table 1: Baseline characteristics  
The effect size observed in that study was d=0·58 and the between-group e ect size was d=0·64. 
A power calculation with 80% power and α set at 0·05 with d=0·64 would result in a total 
sample size of 80 participants. We See Online for appendix B and C  
using ANCOVA models. Here, change from baseline (calculated by subtracting pre-treatment 
scores from post-treatment scores) of the outcome measure was entered as the dependent 
variable and baseline scores as the covariate. As recommended by EMA, this model did not 
include treatment by covariate interactions. We treated missing data as last observation carried 
forward (LOCF) in the primary intention-to-treat analysis. We provide mixed models and 
multiple imputations (20 imputations using sex, age, group, and baseline BDI as predictors) as 
sensitivity analyses. We also include an analysis of patients with complete data before and after 
the treatment period (as per protocol). Raw data of the primary outcome BDI as well as imputed 
datasets are available in appendix B and appendix C, respectively.  
We analysed dichotomous endpoints indicating caseness (BDI below vs above the cuto ; 
diagnosis of major depressive disorder based on the MINI structured interview) using Cochran’s 
χ2 test. All analyses of caseness were restricted to patients in whom caseness was established 
before and after intervention (as per- protocol sample). We used the categorical analyses to 
provide estimates for number needed to treat. Type I error was set at 5% and all tests were 
two-tailed. We provide e ect sizes as Cohen’s d ([change Deprexis minus change WLC] divided 
by SD of the change score). We used PASW statistics software (version 18.0) for all analyses.  
This trial is registered with ClinicalTrials.gov, number NCT01663649.  
Figure 2: E ects of Deprexis on Beck Depression Inventory (BDI) scores Datapoints are mean score and error bars are SD.  
conservatively estimated the sample size at 100 patients because the e ect size in psychiatric 
disorders might not readily be translated to patients with neurological disorders and comorbid 
depression.  
Visual inspection of Q-Q plots suggested normal distribution of data. Therefore, we did 
statistical analyses using parametric tests. According to guidelines for statistical analysis of 
clinical trials published by the European Medicines Agency (EMA; codes CPMP/ ICH/363/96 
and CPMP/EWP/2863/99), we did an intention-to-treat analysis for the primary outcome (BDI)  
-insert table here- 
Data are mean (SD) unless otherwise stated. BDI=Beck Depression Inventory. FSMC=Fatigue scale for Motor and Cognitive 
function. HAQUAMS=Hamburg Quality of Life Questionnaire for Multiple Sclerosis. WHO QoL BREF=WHO Quality of Life 
scale.  
Table 2: Treatment effects  
Role of funding source  
The funding sources did not play any role in data collection, analysis, and interpretation of the 
data. The corresponding author had full access to all of the data and the nal responsibility to 
submit for publication.  
Results  
Patients were enrolled from July 16, 2012, to Oct 22, 2013. We screened 241 patients and 
randomised 90 to either the Deprexis or the control group ( gure 1). The number of patients who 
did not complete the 9-week trial period was similar between the two groups (Deprexis n=10 
[22%]; control n=9 [20%]). Baseline characteristics were much the same between the two groups 
(table 1).  
Analysis of the primary endpoint BDI showed a statistically signi cant treatment e ect of 
Deprexis ( gure 2 and table 2). Group di erences were slightly larger in the mixed models, 
multiple imputations, and the per-protocol analyses (appendix A).  
BDI subscale analyses showed signi cant treatment e ects on the subdomains of negative attitude 
towards self and somatic symptoms (table 2).  
We also analysed the BDI as a categorical variable (BDI 0–13 vs BDI >13) in the per-protocol 
sample post- hoc analysis). Between baseline and week 9, the number of patients above the cuto 
for clinical depression decreased in the Deprexis group and increased in the control group (p for 
between-group treatment di erence=0·01; gure 3). Based on the BDI categorical analysis, the 
number needed to treat was eight.  
34 participants (Deprexis n=17; control n=17) from the online cohort volunteered to undergo 
additional psycho- diagnostic assessment. In this subsample, we con rmed a positive treatment e 
ect of Deprexis on the BDI (LOCF p=0·047; d=0·75; appendix A). Similarly, depressive 
symptoms along DSM-IV diagnostic criteria as measured by the IDS showed a signi cant 
treatment e ect (LOCF p=0·02; d=0·95; appendix A). Furthermore, we detected treatment e ects 
in the IDS cognitive subscale (LOCF p=0·02, d=0·88) but not in the somatic subscale (appendix 
A). The proportion of patients meeting diagnostic criteria for major depressive disorder (as 
determined by the MINI, per protocol) decreased from baseline to 9 weeks but the di erence 
between Deprexis and control was not statistically signi cant (p=0·079; appendix A). On the 
basis of the MINI analysis, the number needed to treat was three.  
When assessing quality of life, as measured by the WHO-QoL BREF, we saw a treatment di 
erence only in the psychological wellbeing subscale (table 2). When assessing the Fatigue Scale 
For Motor and Cognitive Function (FSMC), we saw improvement with intervention versus 
control in only the motor fatigue subscale (table 2) but not on cognitive fatigue symptoms (table 
2). We saw no di erence in any of the disease-speci c quality-of-life (HAQUAMS) subscales 
(table 2).  
Figure 3: E ects of Deprexis on dichotomised Beck Depression Inventory (BDI) Patients were grouped as either below the 
cuto for clinical depression (BDI score 0–13) or with scores indicative of clinical depression (BDI score >13).  
On average, patients allocated to the Deprexis group spent 332 min (about 5·5 h) working with 
the programme (median 310 min; range 50–905). Patient satisfaction with the programme was 
high and most participants reported that the intervention met or exceeded their expectations 
(appendix A). Additionally, many of the participants indicated that they would recommend 
Deprexis to others with mild-to-moderate depression and speci cally those with multiple 
sclerosis. Only a few participants indicated that they needed assistance in handling the 
programme (n=6, 17%). However, about three-quarters (n=27, 77%) of the participants stated 
that they had to force themselves to complete all the sessions, and more than half (n=18, 51%) 
suggested that the programme might require some adjustments to suit the needs of patients with 
multiple sclerosis.  
None of the enrolled participants met the prede ned criterion for acute risk of suicide (response 
3a or 3b on SBQ-R item 3 plus score of 5 or 6 on SBQ-R item 4) at baseline or the 9-week 
assessment. For the low-threshold de nition using BDI item 9, the criterion was not met by any 
patient in the Deprexis group (baseline n=0; 9 weeks n=0) but was met in one instance in the 
control group (n=1; n=1). For SBQ-R item 4, two patients met the low-threshold criterion at 
baseline and no patients met it at week 9 in the Deprexis group. In the control group, four 
patients met this criterion at both baseline and 9 weeks. However, using the low-threshold 
criteria, we saw no evidence of new occurrences of suicidal ideation during the trial in either 
group. We saw worsening of depressive symptoms during the trial from below to above the cuto 
for caseness (BDI >13) in three patients in the control group but none in the Deprexis group.  
All 35 patients assigned to Deprexis and included in the 9-week analysis also completed the 
6-months’ follow-up examination. At 6 months, BDI scores in these participants were lower than 
at baseline (mean BDI at baseline 19·37 [SD 9·59]; mean BDI at 6 months 14·80 [10·03]; 
p=0·001).  
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Panel: Research in context  
Systematic review  
We searched Pubmed for relevant studies using the search terms “depress* AND multiple 
sclerosis AND (intern* OR comput*) AND (therap* OR intervention OR treatment)”. The 
search was restricted to English or German publications and carried out in April 2012, without 
date restrictions. We also browsed reference lists of relevant papers and our own libraries. We 
retrieved 80 articles, eight of which described trials of interventions in multiple sclerosis. Of 
these, two described internet-based interventions in multiple sclerosis (one uncontrolled study 
and one small randomised trial targeting fatigue in multiple sclerosis). Thus, we concluded that a 
phase 2 randomised controlled trial of an internet-based intervention for depression in multiple 
sclerosis was warranted.  
Interpretation  
Our findings show that a fully automated, internet-based cognitive behavioural therapy (CBT) 
intervention is feasible and effective in patients with multiple sclerosis and self- reported 
depressive symptoms, adding to evidence that CBT is an effective treatment strategy in multiple-
sclerosis-associated depression. The ability to provide patients with a self-guided, remote-access 
CBT intervention as shown in this trial provides new evidence that increases the range of 
therapeutic options available to such patients, at least as an interim solution until psychotherapy 
is available. Such options might be particularly relevant for patients with mobility or cognitive 
problems as well as pronounced fatigue, which could a ect their ability to regularly attend 
sessions with a therapist. Furthermore, it o ers patients who do not live close to care centres a 
low- barrier access to treatment. In times of increasingly restricted health-management costs, 
such online CBT interventions might o er a cost-e ective approach.  
Discussion  
We saw reduced depression scores, as measured by the BDI, in patients with multiple sclerosis 
participating in a 9-week iCBT intervention (Deprexis) compared with those not participating in 
the intervention. Importantly, Deprexis not only reduced severity of depressive symptoms, but 
also increased quality of life and decreased fatigue, adding to the clinical relevance of the ndings.  
Our results are in accordance with the positive ndings reported in a recent, non-controlled pilot 
study on the feasibility of an online problem-solving programme in multiple sclerosis.30 Our 
results are also in line with randomised trials done in otherwise healthy patients with depression 
and without comorbid somatic disorders, which lends support to the usefulness of iCBT in 
general31 and speci cally the Deprexis programme in patients with major depressive disorder.18,32,33  
Few randomised trials have assessed the e ects of pharmacological or behavioural interventions 
to treat depression in patients with multiple sclerosis. Findings from studies using antidepressant 
pharmacotherapy in this population have suggested some e cacy but also indicatedfrequentside-e 
ects.13CBT-basedpsychotherapy in group or individual settings is e ective in reducing depressive 
symptoms in multiple sclerosis.14 Moreover, CBT administered by telephone has shown 
promising results.16 Although this approach eliminates the need for the patient to travel, it still 
requires availability of a trained psychotherapist. In view of the motor impairment and  
fatigability typically associated with multiple sclerosis, as well as the limited availability of 
psychotherapists, self- guided, automated, internet-based interventions such as Deprexis might 
be particularly useful for patients with multiple sclerosis and a need for depression treatment, at 
least as an interim solution until psychotherapy is available. Another obvious advantage of 
Deprexis and similar interventions is that they can be broken down into smaller modules and 
completed at any time, therefore allowing patients with increased fatigability or de cits in 
cognitive domains such as processing speed or attention to proceed at their own pace. Overall, 
retrospective, subjective ratings lend support to the feasibility and acceptance of Deprexis by 
patients with multiple sclerosis (appendix A).  
Findings from a meta-analysis of iCBT interventions show that guided iCBT is more e ective 
than self-guided treatments and that even a small degree of contact with a clinician (eg, an 
interview or coming to the hospital for assessments) will lead to better outcomes.34 That the e ect 
size seen in the present study in a subgroup of patients undergoing psychodiagnostic assessment 
at our outpatient centre was larger than in the whole sample is in line with this possibility. 
Evidence has suggested that adding short face-to-face consultations in a blended-care design can 
have positive e ects on retention and outcome of iCBT.19 Email support might also be useful.33 
Therefore, the e cacy of interventions such as Deprexis in multiple sclerosis might be further 
enhanced by adding therapist support in one form or another. Whether or not this is indeed bene 
cial remains to be tested in future studies and is an active area of investigation in our research.  
Our study had some limitations. We selected parti- cipants on the basis of self-reported 
depressive symp- toms. A clinical diagnosis of major depressive disorder was not required for 
enrolment, which could have resulted in mild to moderate levels of depressive symptoms in 
participants. A previous study of Deprexis has reported strongest e ects in patients su ering from 
moderate depressive symptoms.32 Assessments of Deprexis in more severe depression in general 
and in multiple sclerosis speci cally are absent. Overall, the group di erences in our study were 
slightly smaller than the one reported before in patients with depression but no comorbid somatic 
disorder.18 This nding might be due to the lower level of depressive symptoms at baseline in our 
study. Alternatively, it could show the need to adjust Deprexis to multiple-sclerosis-speci c 
needs, as indicated by the retrospective appraisal of the programme in our patients. The drop-out 
rate in our study was just above the cuto for class-I evidence although within the range typically 
seen in behavioural interventions35 and low compared with other online interventions.36 
Adherence to an online programme, though, is di cult to predict.37 Furthermore, the sample size 
was small, particularly in the clinical subgroup analyses. It remains to be seen if Deprexis e ects 
can be maintained when implemented at a larger scale outside of clinical trials.  
This interventional study provides class-II evidence for the e cacy of an internet-based CBT 
intervention (Deprexis) for the treatment of depressive symptoms in patients with multiple 
sclerosis.38 This nding increases therapeutic options for depression associated with multiple 
sclerosis and might help to overcome treatment barriers such as mobility problems often 
encountered by patients with multiple sclerosis and other chronic health conditions (panel).  
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